TrumpRx: Trump Scores Significantly Lower Prices For Popular Weight Loss Drugs

President Donald Trump announced a sweeping deal on Thursday to slash prices for some of the country’s most sought-after weight loss and diabetes medications, marking a major win for Americans struggling with high out-of-pocket drug costs.

Under the new agreements, pharmaceutical giants Eli Lilly and Novo Nordisk will dramatically reduce prices on GLP-1 drugs, including Zepbound, Wegovy, and Ozempic. These medications, widely used for weight loss and diabetes treatment, currently cost around $1,000 per month. With Trump’s new initiative, prices are expected to fall by hundreds of dollars.

Americans will now be able to access the medications through the federal TrumpRx website for as low as $350 per month, with future reductions planned to bring prices down to $245. Patients on Medicare will only pay $50 monthly, regardless of whether the drug is used for obesity or type 2 diabetes.

“This is the biggest drug in our country,” said Health and Human Services Secretary Robert F. Kennedy Jr., praising the announcement. “It’s the most important of all the announcements we’ve made, and it’s going to have the biggest impact on the American people.”

Kennedy predicted that the initiative could help Americans collectively lose 125 million pounds in the next year, pointing to a significant public health boost.

The deal also includes deep discounts on additional drugs:

• Emgality, a migraine treatment from Eli Lilly, will drop by $443 to $299 per pen.

• Trulicity, a diabetes drug, will be discounted by $598 to $389 per month.

• NovoLog and Tresiba, insulin products by Novo Nordisk, will cost just $35 per month.

In addition to the pricing deal, Trump secured major manufacturing investments to support domestic supply. Novo Nordisk has pledged $10 billion to expand U.S. operations, while Eli Lilly is investing $27 billion into American-based manufacturing.

Oral versions of GLP-1 medications are also in development by both companies and will launch at a planned price of $150 per month on the TrumpRx platform.

This initiative comes as part of Trump’s broader effort to break the pharmaceutical pricing monopoly and increase access to life-changing medications through direct government negotiation. The Trump administration’s latest move signals that, in the fight to lower drug prices, weight loss and diabetes medications are front and center.